Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis
Chimeh, R A; Gafar, F; Pradipta, I S; Akkerman, O W; Hak, E; Alffenaar, J-W C; van Boven, J F M

Published in:
International Journal of Tuberculosis and Lung Disease

DOI:
10.5588/ijtld.19.0754

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis: a systematic review

R. A. Chimeh,1 F. Gafar,2 I. S. Pradipta,2,3,4 O. W. Akkerman,5,6 E. Hak,2,7 J-W. C. Alffenaar,1,8,9,10 J. F. M. van Boven1,7

1Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, and 2Unit of PharmacoTherapy, Epidemiology, and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands; 3Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, and 4Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Jawa Barat, Indonesia; 5Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, 6TB Center Beatrixoord, University Medical Center Groningen, University of Groningen, Haren, 7Medication Adherence Expertise Center of the Northern Netherlands (MAECON), Groningen, The Netherlands; 8Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, NSW, 9Westmead Hospital, Sydney, NSW, 10Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney, NSW, Australia

SUMMARY

BACKGROUND: Despite considerable efforts to globally eradicate TB, and the availability of effective antibiotics, TB elimination goals are falling behind. While non-adherence to TB drug regimens may compromise effective treatment, its full impact is still unknown.

OBJECTIVE: To determine the clinical and economic impact of non-adherence to TB medication on treatment outcomes in drug-susceptible TB patients (DS-TB).

METHODS: A systematic review was performed using PubMed and Embase for studies published between 2009 and 2019 reporting associations between adherence and WHO-defined TB treatment outcomes and economic outcomes in DS-TB patients.

RESULTS: A total of 14 studies were included. Eight focused on the association between non-adherence and death, 2 on treatment failure, 1 study on successful treatment outcome, 1 study on both successful and unsuccessful treatment outcomes and 2 on cost outcomes. Most studies (71.4%) were retrospective cohort or case-control studies. The results showed that non-adherence to TB drug regimens was associated with death, treatment failure and lower cure rates.

CONCLUSION: Non-adherence to TB drugs has a profound impact on both clinical and economic TB outcomes. To reach WHO TB elimination goals, preventing non-adherence and the implementation of cost-effective intervention programmes should receive the highest priority.

KEY WORDS: medication adherence; outcomes; failure; cure; tuberculosis

DESPITE THE EXISTENCE of effective TB medications, TB continued to be the primary cause of death of almost 1.3 million people worldwide in 2017.1 Besides increasing access to TB medicines, monitoring of treatment, including adherence and outcomes, is crucial to achieve global TB control. A treatment success rate of ≥85% was defined as the target for global TB control.1

One of the main barriers to achieving favourable treatment outcomes is drug non-adherence.2-3 Adherence is defined as ‘the extent to which a person’s behaviour to take medicines, to follow a diet, and/or to execute lifestyle changes corresponds with agreed recommendations from a healthcare provider’.3

Non-adherent patients cannot gain optimal benefits of their medication. According to recent studies in non-communicable chronic diseases, non-adherence is associated with worsening conditions, mortality, poorer quality of life and reduction in work productivity.5-6 To achieve the goal of eradicating TB worldwide, it is crucial to improve adherence to treatment among patients. In order to enhance adherence, the importance of providing directly observed therapy (DOT) has been emphasised by the WHO. Two recent systematic reviews, however, showed contrasting effects of DOT, where one found that DOT did not have any significant effect on treatment outcomes compared to self-administered treatment (SAT) and the other did.7-8 This may partly explain the low implementation rates for DOT; however, poor awareness on the impact of non-adherence may also play a role. In order to accelerate

Correspondence to: Job F M van Boven, University Medical Center Groningen, Groningen Research Institute of Asthma and COPD (GRIAC), Hanzeplein 1 (internal postcode EB70), 9700 RB Groningen, The Netherlands. e-mail: j.f.m.van.boven@umcg.nl

the implementation of adherence-enhancing interventions and public health actions, there is a need for systematic and comprehensive evidence on the full societal impact of non-adherence on both clinical and economic parameters. In this systematic review, we aimed to focus on the full clinical and economic impact of non-adherence to TB drug regimens in drug-susceptible TB (DS-TB) patients.

**METHODS**

**Study design**

This systematic review was reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement.\(^9\) The protocol of this study was prospectively registered in the PROSPERO database (https://www.crd.york.ac.uk/prospero) under registration number: CRD42018112142. As this systematic review involved data from published studies, ethics clearance and written informed consent were not required.

**Data sources and search strategy**

A systematic search of the PubMed and Embase databases was conducted using a combination of TB disease, adherence, medication, outcome and study design terms for articles published between January 2009 and September 2019 (for details, see Supplementary Data Section 1). The focus of this systematic review was the clinical impact of non-adherence. As economic studies are not always registered in medical databases, a separate, secondary targeted search was performed to investigate the economic consequences of non-adherence to TB medication (Supplementary Data Section 2).

**Study selection**

Randomised controlled trials (RCTs) and observational studies (cohort, case-control and cross-sectional) reporting both adherence and treatment outcomes as defined by WHO guidelines\(^10\) (Supplementary Table S1) in patients treated for DS-TB were included. DS-TB patients were classified as confirmed DS-TB patients, who were susceptible to all first-line anti-TB drug based on the drug susceptibility testing (DST), and presumed cases, who were treated with first-line anti-TB drugs without DST results.\(^10\) There was no restriction on language or geographical area. Papers without a clear definition of the allowed treatment gap to consider someone non-adherent were excluded. Review articles, commentaries, conference abstracts, editorials and animal studies were also excluded. Of note, treatment interruption was defined as incomplete treatment due to side effects and/or non-adherence;\(^11\) in this systematic review, we focused only on non-adherence. A similar process was followed in the selection of papers reporting on the association of non-adherence with economic outcomes.

All titles, abstracts and finally full texts were retrieved and reviewed independently by RAC and FG. Any discrepancies were resolved by discussion; in case no consensus was reached, a third reviewer was consulted (ISP). Potentially relevant references of the included studies were hand searched and assessed by the first reviewer (RAC), and rechecked by the second reviewer (FG). All of these screening steps were conducted using Rayyan QCRI, a web application for systematic reviews (https://www.rayyan.qcri.org).\(^12\)

**Data extraction**

Using a pre-defined template, one researcher (RAC) first extracted data on study characteristics, population characteristics, duration of follow-up, treatment regimens, definition and measurement of treatment adherence, and relationship between treatment non-adherence and treatment outcomes; this was then checked by the second reviewer (FG).

**Quality assessment**

The quality of the included studies was assessed using the Newcastle–Ottawa Scale (NOS) for observational studies\(^13\) in terms of selection, compatibility between cases and controls, and outcomes or exposures by two reviewers (RAC and FG). Inter-reviewer differences were discussed and resolved by consensus: in case no consensus could be reached, a third reviewer was consulted (ISP). (Supplementary Table S2).

**RESULTS**

**Study selection**

The PubMed and Embase searches for clinical studies yielded a total of 3000 articles. After the examination of 211 full-text manuscripts, 12 articles on adherence and clinical outcomes were included. Reference checking of the included studies provided no additional articles. The search for studies evaluating economic impact yielded two additional articles, resulting in a total of 14 articles (Figure 1).

**Study characteristics**

Characteristics of the 12 eligible clinical impact articles are given in Table 1. Most of the studies were retrospective.\(^11,14–21\) Population sizes ranged from 83 to 2416 patients, with mean age varying between 32.7 and 61.2 years.\(^18,22,23\) The number of males was higher than females in all but two studies.\(^14,19\) Patients were mostly treated using a daily dosage of isoniazid, rifampicin, pyrazinamide and ethambutol.\(^15–17,23\)

**Treatment adherence**

Definitions of treatment non-adherence varied across studies, but non-adherence was mostly defined as missing <90% of the prescribed doses\(^16,17,21\) or...
<80% of the prescribed doses.\textsuperscript{18,23} Measurements of adherence also varied, from reviewing treatment charts or pill counts\textsuperscript{14–17,23,24} to self-reports.\textsuperscript{23} In one study, non-adherence mostly occurred in the first months of the treatment, probably due to the improvement in clinical symptoms at the beginning of the treatment.\textsuperscript{22} In contrast, in Chirwa et al.’s study,\textsuperscript{24} non-adherence in the continuation phase was more common compared to the intensive phase (22.9% vs. 20.4%).

\textbf{Treatment outcomes}

Most of the studies (\( n = 12 \)) reported unsuccessful treatment (death and treatment failure) as clinical outcomes.\textsuperscript{11,14,23,15–22} Of these, 8 studies reported death,\textsuperscript{11,14,16–21} 2 reported treatment failure,\textsuperscript{15,23} and 2 articles focused on the association of non-adherence with successful treatment outcome\textsuperscript{22,24} (Figure 2 and Supplementary Table S4).

\textbf{Treatment non-adherence and death}

Of the nine studies evaluating the impact of non-adherence on death, seven showed a significantly increased risk of death in non-adherent patients. To note, two studies were carried out in TB-HIV co-infected patients.\textsuperscript{19,21} Essomba et al. considered non-adherence as a significant risk factor for death in TB-HIV co-infected patients, where the probability of death in non-adherent patients was 22.8 times higher than in adherent patients.\textsuperscript{19} Similarly, Zheng et al. reported a 4.5 times higher risk of death in TB-HIV co-infected patients with unsatisfactory adherence than in those with satisfactory adherence.\textsuperscript{21}

Among TB patients without HIV coinfection, a study by Finlay et al. reported a higher proportion of death in the non-adherent group than in the adherent group (23% vs. 16%).\textsuperscript{20} and in Kayigamba et al.’s study,\textsuperscript{16} more patients died in the non-adherent group than in the adherent group (23% vs. 11%). Similarly, a study among hospitalised patients showed that non-adherent patients had a 13.42 times higher risk of death than adherent patients.\textsuperscript{17} A study of TB patients with or without diabetes mellitus reported that poorly adherent patients were 2.11 times more likely to die than adherent patients.\textsuperscript{18} In another
Table 1  Characteristics of studies reporting clinical and economic outcomes associated with adherence to TB treatment

<table>
<thead>
<tr>
<th>Author country, year</th>
<th>Study design (follow-up)</th>
<th>Population</th>
<th>Medication*</th>
<th>Adherence</th>
<th>Method of the measurement</th>
<th>Clinical outcome</th>
<th>Reported outcome associated with adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zerbini, Argentina, 2017</td>
<td>Retrospective case control</td>
<td>(n = 438); Mean age: 58 years (range: 19–94); Male: 56.7%</td>
<td>Not specified</td>
<td>Patients who took recommended doses were considered adherent</td>
<td>Treatment cards</td>
<td>X</td>
<td>7</td>
</tr>
<tr>
<td>Namukwaya, Uganda, 2011</td>
<td>Retrospective case control</td>
<td>(n = 150); Majority age: &lt;32 years; Males: 63.1%</td>
<td>2RHEZ6EH</td>
<td>Interruption &gt;2 consecutive weeks or missing the scheduled appointment within a week on two or more occasions</td>
<td>Meticulous history taking and interviewing patients, cross-checked using treatment cards</td>
<td>X</td>
<td>7</td>
</tr>
<tr>
<td>Kayigamba, Rwanda, 2013</td>
<td>Retrospective cohort</td>
<td>(n = 581); Median age: 31 (IQR: 25–41); Males: 61.8%</td>
<td>2RHZ4EH</td>
<td>Taking ≥90% of doses</td>
<td>Treatment charts</td>
<td>X</td>
<td>8</td>
</tr>
<tr>
<td>Barennes, Lao PDR, 2010</td>
<td>Retrospective cohort (8 months)</td>
<td>(n = 2416); Mean age: 61.2 years (SD 20.0); Males: 65.7%</td>
<td>2RHZ6EH, 2SRHZ6HE and others</td>
<td>Taken at least 90% of doses</td>
<td>Pill counts and cross-checked with monthly visit data of district hospital</td>
<td>X</td>
<td>4</td>
</tr>
<tr>
<td>Degner, Taiwan, 2018</td>
<td>Retrospective cohort</td>
<td>(n = 1164); Median age: 30–39 years, depending on treatment group (mean not reported); Males: 57.65%</td>
<td>FDC: New cases: 6 months HRZE; Retreated cases: 8 months HRZES</td>
<td>Intermittence ≥ 2 consecutive months</td>
<td>Interview with structured questionnaire</td>
<td>X</td>
<td>3</td>
</tr>
<tr>
<td>Finlay, South Africa, 2012</td>
<td>Retrospective case control</td>
<td>(n = 1164); Median age: 30–39 years, depending on treatment group (mean not reported); Males: 57.65%</td>
<td>Not specified</td>
<td>Five categories: fully adherent, missed ≤20% of doses, missed about one half of the doses, missed most doses, and not adherent at all</td>
<td>Chart review (monthly home visit, monthly pill count and self-reporting)</td>
<td>X</td>
<td>6</td>
</tr>
<tr>
<td>Kirenga, Uganda, 2014</td>
<td>Prospective cohort (2 years)</td>
<td>(n = 96); Mean age: 32.7 years; Males: 52%</td>
<td>2RHZ6EH</td>
<td>Missed &gt;1 dose during last week before the PSA encounter or missed &gt;1 week during last month before the start of encounter; 2) Ratio between the number of prescriptions dispensed and the theoretical number of orders expected &lt;0.95</td>
<td>Questionnaire</td>
<td>X</td>
<td>7</td>
</tr>
<tr>
<td>Essomba, Cameroon, 2017</td>
<td>Retrospective (6 months from treatment initiation)</td>
<td>(n = 394); Mean age: 39 years (SD 10); Males: 45.9%</td>
<td>Not specified</td>
<td>Intermittence in the prescribed regimen of any duration that resulted in &lt;3 anti-TB drugs during the intensive phase or &lt;2 anti-TB medications in the continuation phase</td>
<td>Medical records</td>
<td>X</td>
<td>8</td>
</tr>
<tr>
<td>Nahid, USA, 2011</td>
<td>Retrospective cohort (18 months)</td>
<td>(n = 565); Mean age: 40.98 years; Males: 80%</td>
<td>1–8 weeks HRZE/18 weeks HRZES</td>
<td>Patients who took recommended doses were considered adherent</td>
<td>Treatment cards</td>
<td>X</td>
<td>7</td>
</tr>
<tr>
<td>Author country, year</td>
<td>Study design (follow-up)</td>
<td>Population</td>
<td>Medication*</td>
<td>Adherence</td>
<td>Reported outcome associated with adherence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------</td>
<td>------------</td>
<td>-------------</td>
<td>-----------</td>
<td>------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viegas, Brazil, 2017</td>
<td>Prospective cohort (n = 83); Mean age: 42.19 years; Males: 59.0%</td>
<td>FDC of RH2ZE/RH</td>
<td>High adherence: Morisky scale score: 8</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Average adherence: 6-8 low adherence: &lt;6</td>
<td>Completed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Low adherence:</td>
<td>Failed</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Death</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chirwa, Malawi, 2013</td>
<td>Descriptive (n = 524); Mean age: 36 years (SD 12.4); Males: 57.6%</td>
<td>FDC: New cases: 2HRZE/4HR Retreatment cases: 2HRZE/4HR + S</td>
<td>Actual number of days of missed treatment (for any duration)</td>
<td>X</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Treatment cards</td>
<td>hospitalised records for 2 initial weeks of treatment and community DOT or hospital DOT for the rest of the treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zheng, China, 2015</td>
<td>Retrospective (1 year) (n = 519); Median age: 46 years; Males: 84.39%</td>
<td>2H3R3Z3E3/4H3R3 2HRZE/4HR 2H3R3Z3E3/4H3R3S3/6H3R3E3 and other regimens (not specified)</td>
<td>Completing &gt;90% of prescribed doses is defined as adherence</td>
<td>X</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical records</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budgell, South Africa, 2018 (n = 88); Median age: 4 years; Males: 55.7%; (n = 481); Median age: 39 years; Males: 67.8%</td>
<td>Prospective cohort study (median: 6.4 months)</td>
<td>Daily fixed-dose 2HRZE/4HR Daily dose 2HRZ/4RH</td>
<td>Interruption &gt;2 consecutive months</td>
<td>T8 clinic cards</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Le, China, 2016</td>
<td>Prospective cohort study (6 months)</td>
<td>2H3R3Z3E3/4H3R3</td>
<td>Missed ≥1 dose of drugs or follow-up appointment</td>
<td>Self-design questionnaires cross-checked by patient’s treatment cards</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Numbers before the letters indicate the duration in months of the phase of treatment; numbers in subscript indicate the number of times the drug is taken each week.

TB = tuberculosis; NOS = Newcastle–Ottawa Scale; R = rifampicin; H = isoniazid; E = ethambutol; Z = pyrazinamide; IQR = interquartile range; SD = standard deviation; S = streptomycin; FDC = fixed-dose combination; PSA = psychosocial agents; DOT = directly observed treatment.
study, Nahid et al. investigated the causes of death in pulmonary DS-TB patients. They found that non-adherent patients (56.8%) had a significantly increased rate of death compared to adherent patients (20.8%) during the intensive phase of treatment (hazard ratio, 3.2). They did not find a statistically significant association in the continuation phase, although the number of deaths in non-adherent patients during the continuation phase was numerically higher (30.3% vs. 20.7%).

In contrast, a small study by Viegas et al. reported no significant association between non-adherence and death. In their study, most of the patients adhered to treatment, and 2.4% of patients died because of the non-TB-related causes. A study among pulmonary and extrapulmonary TB patients with or without HIV coinfection reported a non-significant association between death and treatment non-adherence.

Non-adherence and treatment failure

Two studies evaluated the association between non-adherence and treatment failure (for definitions, see Supplementary Table S1). Namukwaya et al. showed that poorly adherent patients had a 14.7 times higher risk of treatment failure than adherent patients. Likewise, in hospitalised TB and TB-HIV co-infected patients, more non-adherent patients failed treatment than adherent patients (25% vs. 21%).

Non-adherence and treatment success

Two articles describing the association between adherence and treatment success were identified. Chirwa et al. showed that the proportion of non-adherent patients who achieved cure during the intensive phase of treatment was 9.6 times lower than those who fully adhered to treatment. However, the number of missing doses during the continuation phase had no significant influence on the cure. Viegas et al. reported a lower cure rate in Brazilian TB patients with low adherence (4.8%) and average adherence (10.8%) than in patients with high adherence (61.5%).

Adherence and cost consequences

Two studies reporting the association between adherence and costs were identified (Tables 1 and 2). Budgell et al. showed that among children and adolescents the average treatment costs for one non-adherent patient was US$33.81 lower than adherent patients (US$108.86 vs. US$142.67). In this study, the costs of medication, laboratory tests, outpatient

<table>
<thead>
<tr>
<th>Study</th>
<th>Non-adherent Cost (Patients, n)</th>
<th>Adherent Cost (Patients, n)</th>
<th>Relative outcomes</th>
<th>Significance P value</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budgell²⁵</td>
<td>US$15.93 (1)</td>
<td>US$27.65 (79)</td>
<td>NR</td>
<td>NR</td>
<td>Medication cost</td>
</tr>
<tr>
<td></td>
<td>US$0.00 (1)</td>
<td>US$8.62 (79)</td>
<td>NR</td>
<td>NR</td>
<td>Laboratory monitoring tests</td>
</tr>
<tr>
<td></td>
<td>US$38.21 (1)</td>
<td>US$43.74 (79)</td>
<td>NR</td>
<td>NR</td>
<td>Outpatient visits</td>
</tr>
<tr>
<td></td>
<td>US$54.73 (1)</td>
<td>US$62.66 (79)</td>
<td>NR</td>
<td>NR</td>
<td>Fixed cost</td>
</tr>
<tr>
<td></td>
<td>US$108.86 (1)</td>
<td>US$142.67 (79)</td>
<td>NR</td>
<td>NR</td>
<td>Average treatment cost</td>
</tr>
<tr>
<td>Lei²⁶</td>
<td>≤RMB 450 (74)</td>
<td>≤RMB 450 (172)</td>
<td>aOR: 2.08 (1.35–3.19)</td>
<td>&lt;0.001</td>
<td>Monthly treatment (median cost: RMB 450, including self-paid TB drugs, liver protecting drugs, cough remission drugs, travelling, accommodation and nourishment)</td>
</tr>
<tr>
<td></td>
<td>&gt;RMB 450 (99)</td>
<td>&gt;RMB 450 (136)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NR = not reported; aOR = adjusted odd ratio; RMB = renminbi.
visits and fixed costs (rental cost of the health care centre, the facilities and staff salaries) were respectively US$11.72, US$8.62, US$5.53 and US$7.93 higher in adherent patients. In contrast, in another study, patients with higher total treatment costs were more likely to be non-adherent. Treatment costs was defined as direct costs of self-paid TB drugs, liver protecting and cough remission drugs, travelling and accommodation.26

DISCUSSION

Main findings
The vast majority of reviewed studies showed significantly higher risks of death, treatment failure and decreased cure rates among drug non-adherent than adherent DS-TB patients. Although the findings of two studies were non-significant due to limited power and small sample sizes,14,22 these agreed with the other studies. Measurement of drug adherence was most commonly conducted by assessment of treatment charts during hospital or home visits. Although this is a simple and cheap method, especially in large populations, the reliability of these data depend on the quality of registration at the health centre.27 For example, in one study,11 135 of 700 patients were excluded due to incomplete medical records, and this could result in an underestimation of the outcomes.

According to most studies, there was a significant association between the degree of adherence and outcomes. However, in some cases, incomplete information on HIV status, multidrug-resistant TB and severity of TB14–18,24 may have confounded this association. It is therefore difficult to rule out the effects of these variables on the outcomes, and this may have led to an overestimation of the impact of non-adherence on treatment outcomes.

Of note, our results indicate an association between the timing of non-adherence and treatment outcomes. In Nahid et al.,11 non-adherence during the intensive phase of treatment was significantly related to death but this was not the case in the continuation phase. These findings are in line with another study,24 in which patients non-adherent in the intensive phase were less likely to be cured than those non-adherent in the continuation phase of the treatment. These findings could be explained by the higher importance of the bactericidal mechanism during the intensive phase than in the continuation phase, as the rate of bactericidal activity is higher immediately after the start of the treatment.28

Regarding the association between adherence and economic outcomes, the evidence was mixed. In one small study (n = 80), treatment costs were lower in non-adherent patients; however, only one patient was non-adherent, making equal comparisons between groups difficult.25 Since adherence to medication in this study increased the medication cost, outpatients visit and laboratory costs, study findings highlighted the importance of financial support in increasing treatment adherence, and subsequently achieving better treatment outcomes. In a larger prospective study, the total (pharmaceutical and non-pharmaceutical) treatment costs were higher in non-adherent patients.26 Given the lack of details on the specifics of the treatment costs (e.g., severity of TB, hospitalisations and additional medications), it is difficult to quantify the exact economic impact of non-adherence. More studies on the economic impact of non-adherence to TB treatment are therefore required.

Limitations
Following a rigorous and systematic approach, this review is the first to provide insights into the full clinical and economic impact of non-adherence to TB medication in DS-TB patients. Nevertheless, our review had some limitations that need to be discussed. First, due to the scarcity of studies in this particular field, we did not limit our study selection to specific high-quality study designs, methodologies or adherence definitions. Therefore, the data obtained were extremely heterogeneous, which made it difficult to synthesise quantitative results and perform a meta-analysis. Only a descriptive data synthesis based on preliminary searches and expert opinion of the authors could be performed. Of note, efforts are currently being made to standardise the adherence taxonomy in respiratory medicine, but this is not accepted by all researchers in the field of TB.29 Second, in order to focus on the impact of non-adherence in terms of recent TB drug regimens and treatment outcomes as defined by WHO, we limited the studies to the last decade, and this may have excluded relevant historical studies. Finally, the low number of articles reporting on the association between non-adherence and costs made it difficult to draw firm conclusions; however, we have added the economic consequences of non-adherence to this systematic review to emphasise the important role played by financial support in increasing adherence and in encouraging further investigation into the economic aspects of non-adherence.

Implications for future research, policy and practice
Given that non-adherence to TB treatment has been strongly associated with worse outcomes, it is of utmost importance to identify factors that lead to non-adherence and provide effective and cost-effective adherence-enhancing interventions. It should be noted that interventions to enhance adherence to TB treatment include directly observed therapy (DOT), digital health technologies such as video-observed therapy (VOT), educational strate-
gies and financial incentives.\textsuperscript{30,31} Specific vulnerable groups of patients to be targeted include older patients, HIV-TB co-infected patients, TB patients with comorbidities and low-income patients.\textsuperscript{32} Furthermore, as most unsuccessful treatment outcomes are associated with non-adherence during the intensive phase,\textsuperscript{11,12,24} it is especially important to focus efforts on this phase.

Looking ahead, more evidence on the temporal association between the duration of non-adherence to TB treatment and the occurrence of outcomes is required.\textsuperscript{33} Such studies may help to set a standard definition for clinically relevant non-adherence, which will lead to the harmonisation of future studies and more precise results. Also, we recommend that prospective studies in larger populations of TB patients be conducted, as this design is less prone to missing data and selection bias.

In conclusion, there is a clear association between non-adherence to TB treatment and both clinical and economic outcomes in patients with DS-TB. Non-adherence to TB medication requires increased attention from healthcare providers and policy makers alike.

\textbf{Acknowledgements}

The authors would like to thank our colleagues at the University Medical Center Groningen (UMCG; Groningen, The Netherlands), S van der Werf for helping with developing the search strategy, and D Xie for translation of the Chinese article, and the UMCG Central Medical Library for providing full texts of articles.

Conflicts of interest: none declared.

\textbf{References}


CONTEXTE : En dépit d’efforts considérables d’éradication de la TB, et de la disponibilité d’antibiotiques efficaces, les objectifs d’élimination de la TB ont pris du retard. Si la non adhérence aux protocoles de médicaments de la TB est susceptible de compromettre l’efficacité du traitement, son impact d’ensemble reste inconnu.

OBJECTIF : Déterminer l'impact clinique et économique de la non observance des médicaments de la TB sur les résultats du traitement parmi les patients TB pharmacosensibles (DS-TB).

MÉTHODE : Une revue systématique a été réalisée sur PubMed et Embase à la recherche d’études, publiées entre 2009 et 2019, rapportant des associations entre adhérance et résultats du traitement définis par l’OMS et des résultats économiques chez des patients DS-TB.

RÉSULTATS : Au total, 14 études ont été incluses. Huit étaient focalisées sur l’association entre non adhérence et décès ; deux, sur l’échec du traitement ; une étude sur les bons résultats du traitement ; une étude à la fois sur les bons et mauvais résultats du traitement et enfin deux sur les résultats en termes de coût. La majorité des études (71,4%) ont été des cohortes rétrospectives ou des études cas témoins. Les résultats ont montré que la non adhérence aux protocoles de traitement de la TB avait été associée au décès, à l’échec du traitement et à des taux de guérison plus faibles.

CONCLUSION : La non adhérence aux médicaments de la TB a un impact profond à la fois sur les résultats cliniques et économiques de la TB. Si l’on veut atteindre les objectifs OMS d’élimination de la TB, la prévention de la non adhérence et la mise en œuvre de programmes d’intervention rentables devraient bénéficier de la plus haute priorité.